Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics

Viruses

Volumn 2, Issue 9, 2010, Pages 1918-1932

  Parker, Scott ^a   Siddiqui, Akbar M ^a   Painter, George ^b   Schriewer, Jill ^a   Buller, R Mark ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Chimerix Inc   (United States)

Author keywords

Animal model; Antiviral; CMX001; Ectromelia; Infection route; Monkeypox; Mousepox; ST 246; Variola

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; IMIQUIMOD; INTERLEUKIN 4 ANTIBODY; TECOVIRIMAT; VACCINIA ANTIBODY;

ANIMAL USE; AREA UNDER THE CURVE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DISEASE SIMULATION; DOSE CALCULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; ECTROMELIA VIRUS; ECZEMA; HUMAN; HUMAN ADENOVIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INNATE IMMUNITY; LD 50; LICENSING; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE STRAIN; MOUSEPOX; NONHUMAN; POXVIRUS INFECTION; PROVOCATION TEST; REVIEW; SKIN DEFECT; SMALLPOX; VACCINATION REACTION; VACCINIA; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

ANIMALIA; ECTROMELIA VIRUS; MONKEYPOX VIRUS; MUS; ORTHOPOXVIRUS; VARIOLA; VARIOLA VIRUS;

EID: 79952169957     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2091918     Document Type: Review

References (53)

1. Marchal, J. Infectious ectromelia. A hitherto undescribed virus disease in mice. J. Pathol. Bacteriol. 1930, 33, 713-728.
2. Fenner, F. Mousepox (infectious ectromelia): past, present, and future. Lab. Anim. Sci. 1981, 31, 553-559.
3. Buller, R.M.; Palumbo, G.J. Poxvirus pathogenesis. Microbiol.Rev. 1991, 55, 80-122.
4. Buller, R.M.L.; Fenner, F. The mouse in biomedical research. Elsevier: New York, NY, USA, 2007; p 67-92.
5. Dick, E.J., JrKittell, C.L. Meyer, H. Farrar, P.L., Ropp, S.L., Esposito, J.J. Mousepox outbreak in laboratory mouse colony. Lab. Anim. Sci. 1996, 46, 602-611.
6. Buller, R.M.; Potter, M.; Wallace, G.D. Variable resistance to ectromelia (mousepox) virus among genera of Mus. Curr. Top. Microbiol. Immunol. 1986, 127, 319-322.
7. Parker, S.; Handley, L.; Buller, R.M. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virology 2008, 3, 595-612.
8. Fenner, F. The pathogenesis of the acute exanthems; an interpretation based on experimental investigations with mousepox; infectious ectromelia of mice. Lancet 1948, 2, 915-920.
9. Esteban, D.J.; Buller, R.M. Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 2005, 86, 2645-2659.
10. Chaudhri, G.; Panchanathan, V.; Buller, R.M.; van den Eertwegh, A.J.; Claassen, E.; Zhou, J.; de Chazal, R.; Laman, J.D.; Karupiah, G. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 9057-9062.
11. Fang, M.; Lanier, L.L.; Sigal, L.J. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog. 2008, 4, e30.
12. Fang, M.; Sigal, L. Studying NK cell responses to ectromelia virus infections in mice. Methods Mol. Biol. 2010, 612, 411-428.
13. Fang, M.; Sigal, L.J. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J. Immunol. 2005, 175, 6829-6836.
14. Karupiah, G. Type 1 and type 2 cytokines in antiviral defense. Vet. Immunol. Immunopathol. 1998, 63, 105-109.
15. Panchanathan, V.; Chaudhri, G.; Karupiah, G., Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 2006, 80, 6333-6338.
16. Parker, A.K.; Parker, S.; Yokoyama, W.M.; Corbett, J.A.; Buller, R.M. Induction of natural killer cell responses by ectromelia virus controls infection. J. Virol. 2007, 81, 4070-4079.
17. Parker, A.K.; Yokoyama, W.M.; Corbett, J.A.; Chen, N.; Buller, R.M. Primary naive and interleukin-2-activated natural killer cells do not support efficient ectromelia virus replication. J. Gen. Virol. 2008, 89, 751-759.
18. Tscharke, D.C.; Woo, W.P.; Sakala, I.G.; Sidney, J.; Sette, A.; Moss, D.J.; Bennink, J.R.; Karupiah, G.; Yewdell, J.W. Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J. Virol. 2006, 80, 6318-6323.
19. Wang, Y.; Chaudhri, G.; Jackson, R.J.; Karupiah, G. IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J. Immunol. 2009, 183, 3324-3331.
20. Brownstein, D.G. Comparative genetics of resistance to viruses. Am. J. Hum. Genet. 1998, 62, 211-214.
21. Brownstein, D.G.; Bhatt, P.N.; Gras, L.; Budris, T. Serial backcross analysis of genetic resistance to mousepox, using marker loci for Rmp-2 and Rmp-3. J. Virol. 1992, 66, 7073-7079.
22. Brownstein, D.G.; Gras, L. Chromosome mapping of Rmp-4, a gonad-dependent gene encoding host resistance to mousepox. J. Virol. 1995, 69, 6958-6964.
23. Delano, M.L.; Brownstein, D.G. Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J. Virol. 1995, 69, 5875-5877.
24. Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, Z.; Ladnyi, I.D. Smallpox and its eradication. World Health Organisation: Geneva, Switzerland, 1988.
25. Roberts, J.A. Histopathogenesis of mousepox. I. Respiratory infection. Br. J. Exp. Pathol. 1962, 43, 451-461.
26. Parker, S.; Nuara, A.; Buller, R.M.; Schultz, D.A. Human monkeypox: an emerging zoonotic disease Future Microbiol. 2007, 2, 17-34.
27. Jordan, R.; Hruby, D. Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev. Anti. Infect.Ther. 2006, 4, 277-289.
28. Painter, G., Buller, R.M.L., Huggins, J., Moyer, R.W., Painter, W., Doucette, M. The challenge of developing an antiviral agent for the treatment of smallpox using the animal efficacy rule. Future Virology 2006, 1, 173-179.
29. Parker, S.; Siddiqui, A.M.; Oberle, C.; Hembrador, E.; Lanier, R.; Painter, G.; Robertson, A.; Buller, R.M. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 2009, 385, 11-21.
30. Jacoby, R.O.; Bhatt, P.N. Mousepox in inbred mice innately resistant or susceptible to lethal infection with ectromelia virus. II. Pathogenesis. Lab. Anim. Sci. 1987, 37, 16-22.
31. Parker, S.; Buller, R.M. Mousepox disease is dependent on route of infection. In Saint Louis University, Missouri: St Louis, USA, 2010.
32. Hooper, J.W.; Thompson, E.; Wilhelmsen, C.; Zimmerman, M.; Ichou, M.A.; Steffen, S.E.; Schmaljohn, C.S.; Schmaljohn, A.L.; Jahrling, P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 2004, 78, 4433-4443.
33. Adams, M.M.; Rice, A.D.; Moyer, R.W. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J.Virol. 2007, 81, 11084-11095.
34. Jahrling, P.B.; Hensley, L.E.; Martinez, M.J.; Leduc, J.W.; Rubins, K.H.; Relman, D.A.; Huggins, J.W. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15196-15200.
35. Mims, C.A. The response of mice to large intravenous injections of ectromelia virus. II. The growth of virus in the liver. Br. J. Exp. Pathol. 1959, 40, 543-550.
36. Moulton, E.A.; Bertram, P.; Chen, N.H.; Buller, R.M.L.; Atkinson, J.P. The interaction between the host's complement system and the poxviral complement regulatory protein determines the lethality of ectromelia infection. Molecular Immunology 2008, 45, 4113-4113.
37. Meiklejohn, G.K.; Kempe, C.H.; Downie, A.W.; Berge, T.O.; St.Vincent, L.; Rao, A.R. Air sampling to recover variola virus in the environment of a smallpox hospital. Bull. World Health Organisation 1961, 25, 63-67.
38. Downie, A.W.; Meiklejohn, M.; St. Vincent, L.; Rao, A.R.; Sundara, B.V.; Kempe, C.H. The recovery of smallpox virus from patients and their environment in a smallpox hospital. Bull. World Health Organisation 1965, 33, 615-622.
39. Zelicoff, A.P. An epidemiological analysis of the 1971 smallpox outbreak in Aralsk, Kazakhstan. Crit Rev. Microbiol. 2003, 29, 97-108.
40. Parker, S.; Schriewer, J.; Oberle, C.; Robertson, A.; Lanier, R.; Painter, G.; Buller, R.M. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir. Ther. 2008, 13, 863-873.
41. Gronvall, G.K.; Trent, D.; Borio, L.; Brey, R.; Nagao, L. The FDA animal efficacy rule and biodefense. Nat. Biotechnol. 2007, 25, 1084-1087.
42. Parker, S.; Touchette, E.; Oberle, C.; Almond, M.; Robertson, A.; Trost, L.C.; Lampert, B.; Painter, G.; Buller, R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 2008, 77, 39-49.
43. Quenelle, D.C.; Buller, R.M.; Parker, S.; Keith, K.A.; Hruby, D.E.; Jordan, R.; Kern, E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob.Agents Chemother. 2007, 51, 689-695.
44. Vora, S.; Damon, I.; Fulginiti, V.; Weber, S.G.; Kahana, M.; Stein, S.L.; Gerber, S.I.; Garcia-Houchins, S.; Lederman, E.; Hruby, D.; Collins, L.; Scott, D.; Thompson, K.; Barson, J.V.; Regnery, R.; Hughes, C.; Daum, R.S.; Li, Y.; Zhao, H.; Smith, S.; Braden, Z.; Karem, K.; Olson, V.; Davidson, W.; Trindade, G.; Bolken, T.; Jordan, R.; Tien, D.; Marcinak, J. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 2008, 46, 1555-1561.
45. CDC, Progressive vaccinia in a military smallpox vacinee - United States. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 1-4.
46. Bray, M.; Martinez, M.; Smee, D.F.; Kefauver, D.; Thompson, E.; Huggins, J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infec. Dis. 2000, 181, 10-19.
47. Neyts, J.; Leyssen, P.; Verbeken, E.; De Clercq, E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother. 2004, 48, 2267-2273.
48. Smee, D.F.; Bailey, K.W.; Wong, M.H.; Wandersee, M.K.; Sidwell, R.W. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 2004, 190, 1132-1139.
49. Grosenbach, D.W.; Berhanu, A.; King, D.S.; Mosier, S.; Jones, K.F.; Jordan, R.A.; Bolken, T.C.; Hruby, D.E. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 838-843.
50. Quenelle, D.C.; Prichard, M.N.; Keith, K.A.; Hruby, D.E.; Jordan, R.; Painter, G.R.; Robertson, A.; Kern, E.R. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 2007, 51, 4118-4124.
51. Stabenow, J.; Buller, R.M.; Schriewer, J.; West, C.; Sagartz, J.E.; Parker, S. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J. Virol. 2010, 84, 3909-3920.
52. Handley, L.; Buller, R.M.; Frey, S.E.; Bellone, C.; Parker, S. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev. Vaccines 2009, 8, 841-850.
53. Jackson, R.J.; Ramsay, A.J.; Christensen, C.D.; Beaton, S.; Hall, D.F.; Ramshaw, I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol. 2001, 75, 1205-1210.